Biomarker ID | 1579 |
PMID | 25274378 |
Year | 2014 |
Biomarker | (Intergenic) LILRB2–LILRA3 [SNP: rs103294] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.65 (95% CI: 0.45–0.95) |
Effect on Pathways | NA |
Experiment | Gleason Score ≤ 6 Vs Gleason Score ≥ 8 |
Type of Biomarker | Prognostic |
Cohort | 1827 men with Prostate cancer were selected for the study. 675 had Gleason Score ≤ 6 and 231 had GS ≥ 8. 921 had GS=7 |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.024 |
Method Used | QIAamp DNA extraction Kit (QIAGEN) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |